Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bavarian Nordic A/S Presents New Data from Phase II Study of PROSTVAC-Reuters


Monday, 4 Jun 2012 02:41am EDT 

Reuters reported that Bavarian Nordic A/S has presented a number of new data from phase II study of prostate cancer vaccine PROSTVAC at the annual cancer conference of American Society of Clinical Oncology (ASCO) in Chicago, the United States. The preliminary analysis suggests that the combination of PROSTVAC and Sm-153 (Quadramet) in patients with metastatic castration-resistant prostate cancer (mCRPC) is well tolerated with similar toxicity profile to the Sm-153 alone. 

Company Quote

97.0
1.0 +1.04%
16 Apr 2014